Charles River Laboratories Intl. Inc vs 3M Company — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while 3M Company trades at $163.56 (market cap $84.36B). The key difference: 3M Company is far larger — about 5.9× Charles River Laboratories Intl. Inc's market cap, and 3M Company pays a 1.91% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and 3M Company for 169 Days on average.
| CRL | MMM | |
|---|---|---|
Market Cap | $14.23B | $84.36B |
Volume | 1,176,885 | 2,325,301 |
Sector | Health | Industrials |
52-Week High | $310.77 | $183.79 |
52-Week Low | $149.93 | $141.10 |
Typical Hold Time | 33 Days | 169 Days |
Enterprise Value | $17.06B | $93.58B |
Dividend Yield | — | 1.91% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
3M (MMM) trades at $162.12, down 0.93% on the day, with a bearish technical signal and support near $158. The company reported strong Q2 2026 earnings, beating estimates with 5.4% organic growth and a 24.9% adjusted operating margin. Revenue for 2025 was $24.95B with net income of $3.25B, though margins have compressed from prior years. Analysts are mixed with a consensus price target of $191, representing potential upside, but high debt and weak consumer sales pose challenges.
The outlook for MMM is cautiously optimistic amid a genuine turnaround narrative. Investment opportunities include continued operational execution, shareholder returns via dividends and buybacks, and growth in industrial and electronics segments. Key risks involve persistent consumer segment weakness, litigation overhang from PFAS, and macroeconomic pressures affecting demand. The stock's valuation remains elevated with a P/E of 29.06, requiring sustained earnings growth to justify further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →